Excellent service to promote development and send policies to ensure growth

Lu Zhiyuan, vice governor of Shaanxi Province, and his party visited Xi'an Libang Pharmaceutical Co., Ltd. for investigation

On July 3, Lu Zhiyuan, vice governor of Shaanxi Province, and his entourage visited Libang Pharmaceutical for in-depth investigation, and learned about the company's production and operation, scientific and technological research and development, and the development of intelligent manufacturing. Zhang Xiaoning, director of Shaanxi Food and Drug Administration, and Lu Qiang, director of Xi'an Food and Drug Administration, accompanied the delegation. Li Tan, chairman of Libang Pharmaceutical, Ju Jianbo, president of Libang Medical Industry Group, Hui Minquan, general manager of Libang Pharmaceutical, and Hu Huali, director of Libang Pharmaceutical, accompanied them.

During the meeting, Ju Jianbo extended a warm welcome to all the leaders for their visit, and expressed his sincere thanks to the governments at all levels for their support, care and help to Libang over the years! A brief introduction was made from the aspects of enterprise production and operation, innovation and development, personnel training and strategic planning.

During the period, Lu Zhiyuan and his party visited the production workshop, inquired about the production management and quality management in detail, and had a cordial conversation with everyone. Hu Huali introduced the layout, quality management, production process, etc., and focused on the company's investment in the production automation of Limengxin Injection and Libangxitong Injection in recent years and the achievements in improving production efficiency.

Finally, Lu Zhiyuan and his party fully affirmed the achievements of Libang Pharmaceutical in all aspects. Libang Pharmaceutical has strong stamina and a good development trend, and should be supported as a key enterprise in Shaanxi Province. It also stated that 20 million yuan of policy funding support will be given to a class of new drugs developed, and 3 million yuan of policy funding support will be given to drugs that have passed the consistency evaluation of generic drugs. At the same time, relevant provincial departments are required to create a better policy environment to support enterprises to become bigger and stronger. I hope that Libang will continue to build its core competitiveness and enter the era of tens of billions of revenue as soon as possible.

The company will take this survey as an opportunity to continue to make three good drugs with "good curative effect, good quality and good service", continuously improve the GMP management level, strictly control the quality, create more high-quality products, and devote itself to continuously improving product technology and innovation ability, gradually realize the beautiful goals of the enterprise, and make new contributions to the cause of human health.